Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 322

Sort by

Sort Order Select

Journal Articles

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom

Anne Huynh, Romain Buono, Edouard Forcade, Hélène Labussière, Patrice Ceballos, Jerome Cornillon, Quentin Cabrera, Maud D'Aveni, Amine Belhabri, Marie Robin, Raynier Devillier, Nicole Raus, Mauricette Michallet

Blood (2025) 146 (Supplement 1): 4297.

https://doi.org/10.1182/blood-2025-4297

Published: 2025

Journal Articles

Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis

Fadi Haddad, Hagop Kantarjian, Mauricette Michallet, Christophe Bouvier, Ghayas Issa, Koji Sasaki, Julien Bollard, Julie Hildt, Sara Dellasala, Vincent Alcazer, Elias Jabbour, Franck Nicolini

Blood (2025) 146 (Supplement 1): 5550.

https://doi.org/10.1182/blood-2025-5550

Published: 2025

Journal Articles

Secondary-type acute myeloid leukemia is associated with a higher risk of invasive fungal infection during intensive induction therapy. a correlative study on the ALFA 0702 trial.

Blood (2025) 146 (Supplement 1): 994.

https://doi.org/10.1182/blood-2025-994

Published: 2025

Journal Articles

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

Blood (2025) 146 (Supplement 1): 3398.

https://doi.org/10.1182/blood-2025-3398

Published: 2025

Journal Articles

Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry

Blood (2025) 146 (Supplement 1): 2450.

https://doi.org/10.1182/blood-2025-2450

Published: 2025

Journal Articles

Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group

Adrien Contejean, Pierre Chauvelot, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Martin Carre, Emmanuelle Tavernier, Jérôme Cornillon, Clémence Santana, Clément Rocher, Sylvain Lamure, Natacha Mauz, Ugo Thévenet, Boullanger Fow Heng Nadine, Gian Matteo Pica, Arthur Dony, Amine Belhabri, Mauricette Michallet, Zofia Gross, Mael Heiblig

Blood (2024) 144 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2024-207605

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Urbain Tauveron-Jalenques, Zofia Gross, Martin Carre, Emmanuelle Tavernier, Jérôme Cornillon, Adrien Contejean, Clemence Santana, Clément Rocher, Sylvain Lamure, Natacha Mauz, Ugo Thévenet, Boullanger Fow Heng Nadine, Pica Gian-Matteo, Dony Arthur, Amine Belhabri, Mauricette Michallet, Pedro Chorao, Mael Heiblig, Gaspar Aspas Requena

Blood (2024) 144 (Supplement 1): 3564.

https://doi.org/10.1182/blood-2024-208577

Published: 2024

Journal Articles

Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group

Mael Heiblig, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Jérome Cornillon, Martin Carre, Mathieu Meunier, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Zofia Gross

Blood (2024) 144 (Supplement 1): 846.

https://doi.org/10.1182/blood-2024-207764

Published: 2024

Journal Articles

Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Martin Carre, Mathieu Meunier, Zofia Gross, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Jérome Cornillon, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Mael Heiblig

Blood (2024) 144 (Supplement 1): 4335.

https://doi.org/10.1182/blood-2024-208817

Published: 2024

Journal Articles

Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group

Emmanuelle Tavernier, Jérôme Cornillon, Zofia Gross, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Martin Carré, Mathieu Meunier, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Mael Heiblig

Blood (2024) 144 (Supplement 1): 1518.

https://doi.org/10.1182/blood-2024-203496

Published: 2024

Journal Articles

Long-Term Outcome of Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation (ASCT) - Impact of Therapeutic Strategy Following ASCT

Emilie Martin, Stéphane Morisset, Mohamad Sobh, Alfred Quillon, Hélène Boyer, Philippe Rey, Emmanuelle Nicolas-Virelizier, Amine Belhabri, Yann Guillermin, Laure Lebras, Valérie Mialou, Jean Paul Bourgeot, Melinda Teyssier, Anne-Sophie Michallet, Mauricette Michallet

Blood (2023) 142 (Supplement 1): 6682.

https://doi.org/10.1182/blood-2023-182700

Published: 2023

Journal Articles

Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group

Zofia Gross, Urbain Tauveron-Jalenques, Gaspar Aspas Requena, Martin Carre, Mathieu Meunier, Emmanuelle Tavernier, Jérôme Cornillon, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Boullanger FOW HENG Nadine, Daciana Claudia Antal, Gian Matteo Pica, Dony Arthur, Clémence Santana, Clement Rocher, Mael Heiblig

Blood (2023) 142 (Supplement 1): 590.

https://doi.org/10.1182/blood-2023-187331

Published: 2023

Journal Articles

Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Michael Mauro, Ronald Paquette, Rüdiger Hehlmann, Loretta A. Williams, Stuart L. Goldberg, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S. DeGutis, Ali McBride, Lori Parsons, Monica Z. Montelongo, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 9624–9625.

https://doi.org/10.1182/blood-2022-163080

Published: 2022

Journal Articles

Long-Term Persistence of Mixed Full Donor Chimerism after Double Cord Blood Transplantation. Example of Tolerance in Allogeneic Hematopoietic Cell Transplantation Setting

Carole Saison, Virginie Mathias, Marie Balsat, Fiorenza Barraco, Sophie Ducastelle, Catherine Giannoli, Hélène Labussière-Wallet, Dan Adrian Luscalov, Philippe Moskovtchenko, Valerie Dubois, Mauricette Michallet

Blood (2022) 140 (Supplement 1): 12861–12862.

https://doi.org/10.1182/blood-2022-159961

Published: 2022

Journal Articles

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Blood (2022) 140 (Supplement 1): 12335–12338.

https://doi.org/10.1182/blood-2022-163478

Published: 2022

Journal Articles

Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring

Michael Philippe, Jerome Guitton, Bertrand Favier, Clemence Santana, Emmanuelle Nicolas-Virelizier, Yann Guillermin, Anne-Sophie Michallet, Mauricette Michallet, Amine Belhabri

Blood (2022) 140 (Supplement 1): 6179–6180.

https://doi.org/10.1182/blood-2022-168327

Published: 2022

Journal Articles

A Genomic Approach in High-Grade B Cell Lymphoma with MYC and BCL2 and / or BCL6 Rearrangements: Two Clusters Stood out on Next Generation Sequencing Results

Arsène Vacherot, Emmanuel Beillard, Catherine Chassagne-Clément, Marie-Charlotte Laude, Pierre Sesques, Laure Lebras, Alexandra Traverse-Glehen, Claire Mauduit, Mauricette Michallet, Stéphane Morisset, Anne-Sophie Michallet, Yann Guillermin

Blood (2022) 140 (Supplement 1): 11878–11879.

https://doi.org/10.1182/blood-2022-169510

Published: 2022

Journal Articles

Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study

Jorge E. Cortes, Stuart L. Goldberg, Ronald Paquette, Loretta A. Williams, Rüdiger Hehlmann, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S. DeGutis, Ali McBride, Lori Parsons, Monica Z. Montelongo, Michael Mauro

Blood (2022) 140 (Supplement 1): 3902–3903.

https://doi.org/10.1182/blood-2022-163063

Published: 2022

Journal Articles

Post-Transplantation Cyclophosphamide for Gvhd Prophylaxis in Related and Unrelated Allogeneic Hematopoietic Cell Transplantation: Study from the SFGM-TC Registry

Blood (2021) 138 (Supplement 1): 2883.

https://doi.org/10.1182/blood-2021-151989

Published: 2021

Journal Articles

Real Life Study on Allogeneic Hematopoietic Cell Transplantation Practice According to International Guidelines and Its Impact on Survival in Acute Myeloid Leukemia French Population

Blood (2021) 138 (Supplement 1): 4133.

https://doi.org/10.1182/blood-2021-152571

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom

Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis

Secondary-type acute myeloid leukemia is associated with a higher risk of invasive fungal infection during intensive induction therapy. a correlative study on the ALFA 0702 trial.

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group

Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group

Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group

Long-Term Outcome of Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation (ASCT) - Impact of Therapeutic Strategy Following ASCT

Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group

Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Long-Term Persistence of Mixed Full Donor Chimerism after Double Cord Blood Transplantation. Example of Tolerance in Allogeneic Hematopoietic Cell Transplantation Setting

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring

A Genomic Approach in High-Grade B Cell Lymphoma with MYC and BCL2 and / or BCL6 Rearrangements: Two Clusters Stood out on Next Generation Sequencing Results

Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study

Post-Transplantation Cyclophosphamide for Gvhd Prophylaxis in Related and Unrelated Allogeneic Hematopoietic Cell Transplantation: Study from the SFGM-TC Registry

Real Life Study on Allogeneic Hematopoietic Cell Transplantation Practice According to International Guidelines and Its Impact on Survival in Acute Myeloid Leukemia French Population

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only